EU/3/19/2233: Orphan designation for the treatment of myelofibrosis



On 16 December 2019, orphan designation EU/3/19/2233 was granted by the European Commission to AbbVie Deutschland GmbH & Co. KG, Germany, for navitoclax for the treatment of myelofibrosis.

Key facts

Active substance
Intended use
Treatment of myelofibrosis
Orphan designation status
EU designation number
Date of designation

AbbVie Deutschland GmbH & Co. KG
67061 Ludwigshafen am Rhein
Tel. +44 1628 925033

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating